Phase 2CompletedINTERVENTIONAL
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
ClinicalTrials.gov · NCT02770391 · Registry updated: 2022-06-21
- Condition / research focus
- Prostate Cancer
- Sponsor
- Case Comprehensive Cancer Center
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2016-10-17. Completion: 2020-04-29 (may be estimated). Results are posted in this registry.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Leuprolide acetate (drug) — also listed as: Lupron
- Apalutamide (drug) — also listed as: ARN-509
- Radical prostatectomy (procedure)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Site recruitment: Not reported